TargaGenix Inc.
Stony Brook
About TargaGenix Inc.
was founded in 2013 to develop novel compounds that are effective on both drug-resistant tumors and cancer stem cells. In numerous preclinical models of cancer, including colon, pancreatic, prostate, breast and lung cancers the company’s lead product SBT-1214 has shown to completely eliminate the tumor. Additional studies have shown that SBT-1214 is able to effectively down-regulate “stemness” gene expression and kill cancer stem cells. Additional chemical modifications and a novel fatty-acid based nanoemulsion formulation result in a drug that has improved pharmacokinetics and pharmacodynamics properties as well as reduced toxicity.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $100.0K
- Funding stage: Seed
- Last round: Seed (Sep 2018)
- Website: targagenixinc.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Chemical, Health Care
Canonical: https://fsome.com/organization/targagenix-inc-164915 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.